Colombo South Teaching Hospital, Dehiwala 10350, Sri Lanka.
Faculty of Medicine of University of Colombo, Kynsey Road, Colombo 00800, Sri Lanka.
Med Hypotheses. 2020 Oct;143:109843. doi: 10.1016/j.mehy.2020.109843. Epub 2020 May 18.
SARS-CoV-2 virus has resulted in a devastating pandemic of COVID-19. Exploring compounds that could offer a breakthrough in treatment is the need of the hour. Re-positioning cheap, freely available and safe drugs is a priority. The paper proposes evidence for the potential use of diethylcarbamazine (DEC) in the treatment of COVID-19. DEC has inhibitory effects on arachidonic acid metabolism to prostaglandins, little known anti-viral effects on animal retroviruses and demonstrated anti-inflammatory actions in animal models of lung inflammation indicating the need to explore this hypothesis further. We believe this is the first time DEC is being proposed to treat COVID-19.
严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）引发了 COVID-19 大流行。探索可能在治疗方面取得突破的化合物是当务之急。重新定位廉价、可自由获得和安全的药物是当务之急。本文提出了使用乙胺嗪（DEC）治疗 COVID-19 的潜在用途的证据。DEC 对前列腺素的花生四烯酸代谢具有抑制作用，对动物逆转录病毒具有鲜为人知的抗病毒作用，并在肺部炎症的动物模型中显示出抗炎作用，这表明需要进一步探索这一假说。我们相信，这是首次提出使用 DEC 治疗 COVID-19。
